BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang(Zhongshan People's Hospital), Yong Yuan(Zhongshan People's Hospital), Greg Deener(Io Therapeutics (United States)), Ming Hong(Guangzhou University of Chinese Medicine), M. Wada(Nicolaus Copernicus Astronomical Center), Shanzhi He(Zhongshan People's Hospital), Kevin G. Pinz(Unknown), Zhencong Guo(Zhongshan People's Hospital), Darshi Shah(Stony Brook School), Yingwen Liang(Zhongshan People's Hospital), Wenli Zhang(Peking University Shenzhen Hospital), Ling Ding(Qiqihar University), Min Wang(Zhongshan People's Hospital), Yu Ma(Io Therapeutics (United States)), Hongyu Zhang(Peking University Shenzhen Hospital), Ting Lan(Zhongshan People's Hospital), Yupo Ma(Macau University of Science and Technology), Mingxia Wang(Hebei Medical University), Chanjuan Zou(Zhongshan People's Hospital), Ronghao Zeng(Zhongshan People's Hospital), Nabil Hagag(Io Therapeutics (United States)), V. Destéfano(Io Therapeutics (United States)), Fugui Li(Zhongshan People's Hospital)
Cited by 194
Related Papers
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
|Oncotarget|2016|112
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
|Journal of Virology|2016|81
Stem Cell Gene SALL4 Suppresses Transcription through Recruitment of DNA Methyltransferases
|Journal of Biological Chemistry|2011|71
Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4
|Journal of Hematology & Oncology|2011|57
Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy
|Seminars in Cancer Biology|2022|44